Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to -$8.3 million.

  • Pulmonx's Free Cash Flow fell 834.32% to -$8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 625.27%. This contributed to the annual value of -$33.0 million for FY2024, which is 1414.22% up from last year.
  • As of Q3 2025, Pulmonx's Free Cash Flow stood at -$8.3 million, which was down 834.32% from -$4.0 million recorded in Q2 2025.
  • In the past 5 years, Pulmonx's Free Cash Flow ranged from a high of -$4.0 million in Q2 2025 and a low of -$15.6 million during Q1 2022
  • Over the past 5 years, Pulmonx's median Free Cash Flow value was -$9.9 million (recorded in 2021), while the average stood at -$9.9 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 7231.11% in 2021, then soared by 3687.99% in 2025.
  • Pulmonx's Free Cash Flow (Quarter) stood at -$11.8 million in 2021, then rose by 15.8% to -$10.0 million in 2022, then rose by 13.69% to -$8.6 million in 2023, then rose by 20.55% to -$6.8 million in 2024, then decreased by 20.73% to -$8.3 million in 2025.
  • Its Free Cash Flow was -$8.3 million in Q3 2025, compared to -$4.0 million in Q2 2025 and -$13.5 million in Q1 2025.